These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 38763112)
1. Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanoma. Czarnecka AM; Ostaszewski K; Błoński P; Szumera-Ciećkiewicz A; Kozak K; Placzke J; Borkowska A; Terlecka A; Rogala P; Świtaj T; Sałamacha M; Mitręga-Korab B; Krotewicz M; Dudzisz-Śledź M; Rutkowski P Eur J Surg Oncol; 2024 Jul; 50(7):108382. PubMed ID: 38763112 [TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma. Sharon CE; Tortorello GN; Ma KL; Huang AC; Xu X; Giles LR; McGettigan S; Kreider K; Schuchter LM; Mathew AJ; Amaravadi RK; Gimotty PA; Miura JT; Karakousis GC; Mitchell TC Ann Oncol; 2023 Sep; 34(9):806-812. PubMed ID: 37414215 [TBL] [Abstract][Full Text] [Related]
3. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF Long GV; Saw RPM; Lo S; Nieweg OE; Shannon KF; Gonzalez M; Guminski A; Lee JH; Lee H; Ferguson PM; Rawson RV; Wilmott JS; Thompson JF; Kefford RF; Ch'ng S; Stretch JR; Emmett L; Kapoor R; Rizos H; Spillane AJ; Scolyer RA; Menzies AM Lancet Oncol; 2019 Jul; 20(7):961-971. PubMed ID: 31171444 [TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma. Czarnecka AM; Ostaszewski K; Błoński PJ; Szumera-Ciećkiewicz A; Świtaj T; Kozak K; Koseła-Patreczyk H; Rogala P; Kalinowska I; Zaborowski K; Krotewicz M; Borkowska A; Rutkowski P Cancer; 2024 Oct; 130(20):3463-3472. PubMed ID: 38843386 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468 [TBL] [Abstract][Full Text] [Related]
7. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy]. Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004 [No Abstract] [Full Text] [Related]
16. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer]. Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171 [No Abstract] [Full Text] [Related]